Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also
predispose patients to immune-related adverse events like immune-mediated colitis (IMC) …

Background: Immune checkpoint inhibitors (icis) are increasingly being used in clinical
practice, improving outcomes for cancer patients. Preclinical models showed significant …

Immune-mediated diarrhea and colitis (IMDC) is among the most common immune-related
adverse events in patients with cancer treated with immune checkpoint inhibitors (ICIs) …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune inhibitory
pathways. Administration of ICIs augments T cell-mediated immune responses against …

Background The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI)
therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic …

We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis
successfully treated with fecal microbiota transplantation, with reconstitution of the gut …

Fecal microbiome transplantation (FMT) from healthy donors is one of the techniques for
restoration of the dysbiotic gut, which is increasingly being used to treat various diseases …

Simple Summary The current review assessed the effects of the gut microbiome on clinical
outcomes of immunotherapy and related adverse events (AEs) in cancer patients. Studies …

The equilibrium linking the intestinal microbiota, the intestinal epithelium, and the host
immune system establishes host health and homeostasis, with perturbations of this balance …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in the last decade.
Among various checkpoints identified so far, interaction between programmed death-1 (PD …